Acutaas Chemicals Approves ₹212 Crore Capex Plan, Reappoints Directors
Acutaas Chemicals approved a capital expenditure plan of up to ₹212 crores for a new manufacturing plant in Gujarat. The company re-appointed Mr. Ram Mohan Lokhande as Whole-Time Director and Mrs. Anita Bandyopadhyay as Independent Director for five-year terms starting February 8, 2027. The 19th AGM is scheduled for September 24, 2026.
The substantial capital expenditure plan for a new manufacturing plant focused on electronic grade chemicals is a significant strategic move that is expected to drive future growth and market position.
The announcement details significant capital expenditure for expansion and re-appointment of key management personnel, indicating positive growth and stability for the company.
Acutaas Chemicals Limited (formerly Ami Organics Limited) announced key outcomes from its Board Meeting held on August 22, 2026. The Board approved the notice for the 19th Annual General Meeting (AGM) scheduled for September 24, 2026, at 11:30 a.m. IST, to be conducted via video conferencing. The Annual Report for the financial year 2025-26 was also considered and adopted.
Furthermore, the Board approved the re-appointment of Mr. Ram Mohan Lokhande as Whole-Time Director for five years from February 8, 2027, to February 7, 2032. Mrs. Anita Bandyopadhyay was also re-appointed as Director (Non-Executive & Independent) for a second term of five years, effective February 8, 2027, to February 7, 2032. Both re-appointments are subject to shareholder approval at the upcoming AGM.
The company also approved extending the Ami Organics Employees Stock Option Scheme 2023 (ESOS 2023) benefits to eligible employees of its Indian subsidiaries, pending shareholder approval. A significant capital expenditure plan of up to ₹212 crores was sanctioned for establishing a greenfield/brownfield manufacturing plant in Gujarat. This plant will focus on new electronic grade chemicals and can be undertaken by the company or its subsidiaries. The proposed capacity is up to 81,000 MT per annum, with completion targeted by the end of FY 2027-28. The investment will be financed through internal accruals, bank finances, or other permissible methods.
What to do with a filing like this
Acutaas Chemicals Limited filed this with the NSE as a statutory disclosure, categorised under board meeting. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Acutaas Chemicals Limited. Read the original for the full detail.